HLB Therapeutics' Eye Drug Misses Phase 3 Goal

A Phase 3 trial of RGN-259 for neurotrophic keratitis showed no statistically significant difference from placebo on its primary endpoint.

Updated on Nov. 15, 2026 in Biotech

HLB Therapeutics' Eye Drug Misses Phase 3 Goal

HLB Therapeutics' US subsidiary ReGenTree received top-line results from the Phase 3 SEER-2 trial of RGN-259, a candidate for neurotrophic keratitis, on November 13, 2026. The analysis found no statistically significant difference between the treatment group and the placebo group on the primary endpoint, cure rate after four weeks of administration.

Why it matters

Neurotrophic keratitis is a rare eye disease in which damaged corneal nerves reduce sensation and slow healing, and severe cases can lead to corneal ulcers, perforation and vision loss. The negative primary endpoint leaves patients with the condition without a newly confirmed treatment option from this candidate for now.

The Phase 3 SEER-2 trial measured cure rate after four weeks of administration, and the top-line analysis showed no statistically significant difference between RGN-259 and placebo. Secondary endpoints and subgroup responses have not been reported.

The players

HLB Therapeutics

HLB Therapeutics is a South Korean biopharmaceutical company developing treatments for a range of diseases, including its eye-disease candidate RGN-259.

The details

HLB Therapeutics announced the results on November 16, 2026, three days after its US subsidiary ReGenTree received the top-line data from a contract research organization. The company plans to analyze the full clinical data, including secondary endpoints and treatment responses by patient subgroup, before deciding whether and how to continue development.

Timeline

  1. November 13, 2026: ReGenTree received top-line Phase 3 results from the contract research organization.

  2. November 16, 2026: HLB Therapeutics announced that the primary endpoint was not met.

  3. Within weeks: The company expects to receive the full clinical data.

Landscape

The negative Phase 3 SEER-2 result places RGN-259 among neurotrophic keratitis candidates whose late-stage trials must demonstrate statistically significant efficacy over placebo before approval. The outcome leaves the program's path forward dependent on the full data review.

For people living with neurotrophic keratitis, the negative primary endpoint means RGN-259 is not available as a newly confirmed option based on this trial. Patients should continue to rely on current care and discuss any questions about their eye condition with their eye care provider.

The takeaway

A trial missing its primary endpoint does not end a program automatically, since the full data may reveal secondary benefits or subgroup responses. Readers tracking rare eye-disease treatments should watch for HLB's next decision on RGN-259.

What happens next

HLB Therapeutics expects to receive the full clinical data within weeks and will then decide on the direction of RGN-259 development.

Further reading

Explore more biotech news for context on drug development trials.

Source note: This article includes information reported by 조선일보.